Stocks Health care ADAG
NASDAQ · Health careAdagene Inc. (ADAG)
Adagene Inc. reported revenue of $7.7M in fiscal 2025, up 7,332.8% from a year earlier. It posted a net loss of $17.6M. In fiscal 2025 capital spending exceeded operating cash flow by $15.7M. At December 31, 2025 it held $74.5M in cash against $1.8M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 1, 2026.
What Adagene Inc. does
Adagene Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ADAG.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.7M | -$17.6M | -$0.30 | -$15.7M |
| 2024 | $103.2K | -$33.4M | -$0.59 | -$29.7M |
| 2023 | $18.1M | -$18.9M | -$0.35 | -$28.5M |
| 2022 | $9.3M | -$80M | -$1.48 | -$49.3M |
| 2021 | $10.2M | -$73.2M | -$1.46 | -$45.9M |
| 2020 | $700.9K | -$42.4M | -$2.67 | -$29.5M |
Latest SEC filings
What Adagene Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 22, 2026
- September 10, 2026
- September 9, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- July 6, 2026
- June 8, 2026Activist stake changed SCHEDULE 13D/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026Passive stake (5% or more) SCHEDULE 13G
Questions about ADAG
What does Adagene Inc. do?
Adagene Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ADAG.
Is Adagene Inc. profitable?
No. In fiscal 2025 it reported a net loss of $17.6M on revenue of $7.7M.
How much revenue does Adagene Inc. make?
In fiscal 2025 Adagene Inc. reported revenue of $7.7M. That is 7,332.8% more than a year earlier.
When did Adagene Inc. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 1, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 25, 2026.
Similar companies
Follow ADAG
Get an email when Adagene Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ADAG: get an email when it filesWhere the numbers come from
Financial figures are the values Adagene Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.